LZR‑1SJ: Dual‑Axis In-Silico Autoimmune Resilience for Sjögren's Disease

Background:

Sjögren’s disease is a chronic autoimmune condition marked by lymphocytic infiltration of exocrine glands, epithelial stress and barrier fragility, and interferon‑skewed cytokine milieus that degrade lacrimal and salivary function while enabling systemic involvement in joints, lungs, kidneys, and nerves (Fox, 2005; Ramos‑Casals et al., 2012; Mariette & Criswell, 2018). LZR‑1SJ is a biology‑oriented, governance‑native therapy architecture developed exclusively in silico. It reframes autoimmune pathology as a systems misalignment by distributing selective pressure across two orthogonal axes: “entry suppression” of immune infiltration (adhesion and trafficking constraints) and “replication suppression” of autoreactive amplification loops (checkpoint and stromal feedback control), then sequencing repair through phase‑gated epithelial stabilization, microvascular reinforcement, mitochondrial recovery, and immune resolution (Nocturne & Mariette, 2013; Alunno et al., 2019).

Methods:

Agent‑based cohorts and tissue‑scale digital twins parameterize acinar/ductal epithelial integrity, endothelial adhesion dynamics (ICAM‑1/VCAM‑1 bands), lymphoid focus formation, oxidative stress, and moisture function proxies under variance in interferon signatures, BAFF elevation, hypoxia, fever shifts, and mucosal microenvironment stress (Hjelmervik et al., 2009; Gottenberg et al., 2013; Baer et al., 2013). Orthogonal gating abstractions enforce compartment fidelity and timing hysteresis; layered containment models (RNA knockdown, degron‑based protein clearance, transcriptional repression, cassette‑level off‑ramps) provide reversible shutdown with synthetic telemetry and watermarkable provenance to support auditability and non‑operational disclosure.

Results:

Across heterogeneous interferon‑high and BAFF‑elevated arms, modeled entry suppression reduced immune‑infiltration and adhesion proxies, while replication suppression dampened cytokine oscillations and autoreactive feedback. Phase‑gated repair improved epithelial barrier metrics and local microperfusion, shortened oxidative‑stress tails, and stabilized moisture function proxies when biological dependencies were respected (epithelial → vascular → metabolic → immune), compared to single‑axis engagement (Fox, 2005; Nocturne & Mariette, 2013). Sensitivity analyses preserved phase separability and minimized mis‑timed activations, indicating variance‑aware robustness across patient‑like contexts (Gottenberg et al., 2013; Alunno et al., 2019).

Conclusions:

By treating Sjögren’s disease as a systems‑level misalignment requiring distributed pressure across infiltration and amplification axes, LZR‑1SJ offers a simulation‑native, biology‑grounded framework for coordinated repair under enforceable containment and forensic traceability. The architecture supports hypothesis generation, risk cataloging, and governance‑first dialogue prior to any wet‑lab work, aligning with emerging digital‑twin and systems immunology approaches to pathogenesis and progression in Sjögren’s disease (Ramos‑Casals et al., 2012; Mariette & Criswell, 2018; Sharapova et al., 2022).

Plain language summary

Sjögren’s disease causes the body’s immune system to attack moisture‑producing glands, leading to dry eyes and dry mouth, and sometimes affecting joints, lungs, kidneys, and nerves. LZR‑1SJ is a therapy design that aims to coordinate repair in the right order for these glands and their support systems: first stabilizing the glandular epithelium, then reinforcing local blood supply, then restoring cellular energy, and finally calming overactive immune signals. It is built on biology, but it currently exists only as a simulation. That means everything has been designed and assessed using computer models and “digital twin” tissue environments, not in animals or people.

• What it is: A modular, phase‑by‑phase autoimmune resilience framework that uses biology‑informed switches to turn specific repair programs on and off in the right tissues at the right times.

• How it works (in silico): We use agent‑based simulations of salivary and lacrimal gland microenvironments with chronic inflammation, immune cell infiltration, and cytokine imbalance. In these models, LZR‑1SJ’s control logic limits activity to the intended epithelial and vascular targets, reduces immune “entry” and amplification signals, and provides several independent ways to shut things down if needed.

• Safety by design: The architecture includes modeled “kill switches” at the RNA, protein, transcriptional, and cassette levels, plus reversible gates and forensic “watermarks” that create a traceable audit trail.